中恒集团(600252.SH)公告，2025年4月14日，公司的全资子公司广西中恒创新医药研究有限公司(简称“中恒创新”)收到国家药品监督管理局核准签发的三芪颗粒(规格：每袋装5g)《药物临床试验批准通知书》。根据《中华人民共和国药品管理法》及有关规定，经审查，2025年1月14日受理的三芪颗粒符合药品注册的有关要求，同意本品循序开展用于慢性肾小球肾炎的Ⅱ、Ⅲ期临床试验。

海量资讯、精准解读，尽在新浪财经APP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.